Effectiveness of mRNA BNT162b2 and inactivated CoronaVac vaccines against severe COVID-19 outcomes among non-hospitalised children aged 1-3 years with SARS-CoV-2 Omicron infection
-
Published:2024-03
Issue:3
Volume:63
Page:107094
-
ISSN:0924-8579
-
Container-title:International Journal of Antimicrobial Agents
-
language:en
-
Short-container-title:International Journal of Antimicrobial Agents
Author:
Wong Carlos K.H.ORCID,
Lau Kristy T.K.ORCID,
Au Ivan C.H.ORCID,
Lau Eric H.Y.ORCID,
Cowling Benjamin J.
Reference19 articles.
1. COVID-NET Surveillance Team. Hospitalization of Infants and children aged 0-4 years with laboratory-confirmed COVID-19 - COVID-NET, 14 States, March 2020-February 2022;Marks;MMWR Morb Mortal Wkly Rep,2022
2. Severity of SARS-CoV-2 Omicron BA.2 infection in unvaccinated hospitalized children: comparison to influenza and parainfluenza infections;Tso;Emerg Microbes Infect,2022
3. KidCOVE Study Group. Evaluation of mRNA-1273 vaccine in children 6 months to 5 years of age;Anderson;N Engl J Med,2022
4. Evaluation of BNT162b2 Covid-19 vaccine in children younger than 5 years of age;Muñoz;N Engl J Med,2023
5. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial;Han;Lancet Infect Dis,2021